You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀升巨子生物(02367.HK)目標價至44.9元 降歐舒丹(00973.HK)目標價至26元
瑞銀發表研究報告指,對中國美容護理業今年前景持審慎看法,在宏觀經濟困難、消費者情緒低迷、增長機會有限且成本高昂的情況下,比較看好估值不高、擁有強大內部研發與創新能力、穩健品牌資產及成熟多品牌產品組合的企業。 另外瑞銀亦指出,在紙漿價格下行周期中,預期生活用紙企業盈利前景將復甦。瑞銀首選股為巨子生物(02367.HK),評級「買入」,目標價由43.3元升至44.9元;並對恆安(01044.HK)給予「買入」評級,目標價由36.4元降至33元。 瑞銀預計今年中國化妝品行業銷售額將實現低至中單位數增長,對歐舒丹(00973.HK)給予「買入」評級,目標價則從28.2元降至26元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account